Literature DB >> 9484953

Energetics of vinca alkaloid interactions with tubulin isotypes: implications for drug efficacy and toxicity.

S Lobert1, A Frankfurter, J J Correia.   

Abstract

A number of vinca alkaloids, including vincristine, vinblastine, and vinorelbine, are currently used in cancer chemotherapy. These three vinca alkaloids interact differently with a range of solid and hematologic tumors. To test the possibility that the tubulin isotype composition is an important determinant in antineoplastic efficacy, we determined thermodynamic parameters for vinca alkaloid interactions with purified beta-tubulin isotypes, alphabetaII or alphabetaIII, as well as mixtures of alphabetaII and alphabetaIII, alphabetaII and alphabetaI&IV, or alphabetaIII and alphabetaI&IV (referred to as isotype-depleted tubulin) by quantitative sedimentation velocity. Vincristine-, vinblastine-, or vinorelbine-induced isotype self-association was studied at 25 degrees C in 10 mM Pipes, pH 6.9, 1 mM MgSO4, and 2 mM EGTA in the presence of 50 microM GTP or GDP. For all three drugs, we observed no significant differences in overall affinities, K1K2, or in GDP enhancement of purified isotypes compared to unfractionated tubulin, suggesting that differential antitumor efficacy observed clinically for these vinca alkaloids is not determined by tissue isotype composition. Small, but significant differences in the individual binding parameters, K1 and K2, are found in the vincristine data. In the presence of vincristine and GTP, K1, the affinity of drug for tubulin heterodimers, tends to be larger for purified alphabetaII- or alphabetaIII-tubulin compared to unfractionated tubulin. Furthermore, the apparent dimerization constant, K2app, at physiologically significant drug concentrations is larger for these purified isotypes. When alphabetaII- and alphabetaIII-tubulin are combined, the cooperativity between drug binding and spiral formation approaches that of unfractionated PC-tubulin. These differences are not observed in the presence of vinblastine or vinorelbine. The differences found with vincristine may be implicated in the dose-limiting neurotoxicity found with this drug, but not found with vinblastine or vinorelbine.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9484953     DOI: 10.1002/(SICI)1097-0169(1998)39:2<107::AID-CM2>3.0.CO;2-3

Source DB:  PubMed          Journal:  Cell Motil Cytoskeleton        ISSN: 0886-1544


  7 in total

1.  Investigation of anti-tumor mechanisms of K2154: characterization of tubulin isotypes, mitotic arrest and apoptotic machinery.

Authors:  Pin-Hsuan Lu; Fan-Lu Kung; Sheng-Chu Kuo; Shih-Chieh Chueh; Jih-Hwa Guh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-11-11       Impact factor: 3.000

2.  Different effects of vinblastine on the polymerization of isotypically purified tubulins from bovine brain.

Authors:  Israr A Khan; Richard F Ludueña
Journal:  Invest New Drugs       Date:  2003-02       Impact factor: 3.850

3.  Murine leukemia P388 vinorelbine-resistant cell lines are sensitive to vinflunine.

Authors:  Ashish Aggarwal; Anna Kruczynski; Anthony Frankfurter; John J Correia; Sharon Lobert
Journal:  Invest New Drugs       Date:  2007-12-11       Impact factor: 3.850

4.  A novel submicron emulsion system loaded with vincristine-oleic acid ion-pair complex with improved anticancer effect: in vitro and in vivo studies.

Authors:  Ting Zhang; Yong Zheng; Qiang Peng; Xi Cao; Tao Gong; Zhirong Zhang
Journal:  Int J Nanomedicine       Date:  2013-03-20

5.  Physiologically Based Pharmacokinetic Models for Adults and Children Reveal a Role of Intracellular Tubulin Binding in Vincristine Disposition.

Authors:  Christine M Lee; Nicole R Zane; Gareth Veal; Dhiren R Thakker
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-08-30

6.  Beta class II tubulin predominates in normal and tumor breast tissues.

Authors:  James H Dozier; Laree Hiser; Jennifer A Davis; Nancy Stubbs Thomas; Michelle A Tucci; Hamed A Benghuzzi; Anthony Frankfurter; John J Correia; Sharon Lobert
Journal:  Breast Cancer Res       Date:  2003-07-28       Impact factor: 6.466

7.  Combination of BCL11A siRNA with vincristine increases the apoptosis of SUDHL6 cells.

Authors:  Dongmei He; Hong Wu; Li Ding; Yangqiu Li
Journal:  Eur J Med Res       Date:  2014-06-24       Impact factor: 2.175

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.